Disponible en / Available in: Español
Thanks to the support of the Botín Foundation, the Respiralia Group is committed to digitizing its processes to improve its services.
Digital transformation as a tool for improvement
The quality management that the Respiralia Group has opted for requires a significant human effort. Since the Respiralia Foundation and the Cystic Fibrosis Balearic Association are small entities in terms of administrative staff, but have grown a lot in recent years, it is necessary to provide them with digital tools to facilitate the daily work.
Fundación Botín’s Digital Transformation Program
This program includes the support service of a mentor who will help us in the implementation of the Digital Transformation Plan we need, for a period of 6 months. In addition, we will receive a large number of training pills and live webinars given by its panel of specialists to help us advance in the field of digitization, mainly in three areas: Digital Organization, Fundraising and Visibility of the Organization.
Although the Cystic Fibrosis Balearic Association has been chosen for this program, the Respiralia Group as a whole shares very clear objectives in this digital transformation process:
- Knowing and using the digital tools available to us when carrying out our processes.
- Facilitate access to our activities
- Improving the measurement of the impact of our projects
- Giving greater visibility to our actions
Fundación Botín and Respiralia Group join forces in 2019
Thanks to the Red Talento Solidario program, the Respiralia Group has already received training thanks to the Botín Foundation, thus helping to improve the quality of our programs and services. Our staff has participated in numerous training workshops on digital marketing, legal regulations related to non-profit organizations, project formulation, digital fundraising, etc.
What is Cystic Fibrosis?
Cystic Fibrosis is a genetic, serious and degenerative disease that to date has no cure.
It mainly affects the respiratory, digestive, reproductive and sweat glands.
The treatment for Cystic Fibrosis includes antibiotherapy, a healthy and hypercaloric nutrition and respiratory physiotherapy combined with endurance exercises.
Currently, more than 2000 mutations are known in the gene that is defective in people with Cystic Fibrosis, although only about 150 mutations are described as causing the disease.
Statistics show that 1 in 5,000 people in Spain has Cystic Fibrosis (1 in 6,400 in the Balearic Islands) and 1 in 35 people is a carrier of a gene that causes the disease (1 in 40 in the Balearic Islands).
In the Balearic Islands there are 76 known diagnosed cases, but statistics speak of between 85 and 90 possible cases.
The awareness project of the Respiralia Foundation aims to raise awareness of this disease in order to discover those cases of people who have Cystic Fibrosis but have not yet been diagnosed.